Domainex's newsletter brings you up to speed on the latest announcements from the team.
No images? Click here
Domainex newsletter
All the latest news and industry insights from the Domainex team
Tom Mander, CEO
Awards success recognises our strength in people and partnerships
Well, what a start to 2023 it’s been. As the world attempts to navigate ongoing financial challenges, it has never been more evident how important our people are in building our success. We finished off 2022 on a high, being honoured with two awards at the Cambridge Independent SME awards and a Silver award at the SME National Business Awards. Alongside recently being named Best Drug Development, Discovery and Contract Research Organisation, these awards are a mark of respect for our team's contributions to Domainex and the wider industry.
We were pleased to expand our Executive and Management teams through a number of internal promotions and we’ve also welcomed a number of new people to the Domainex team. I look forward to working with them all on some very exciting projects.
Partnerships have always been vital to expand our capabilities and it was great to welcome some of our partners to our research campuses recently. We’ll be attending several events in the coming weeks so if you’re interested in working with us, please get in touch to set up a meeting.
At the Cambridge Independent SME Awards, we were awarded Silver for Business of the Year (more than 50 employees) and won a Gold award for High Growth Business of the Year. Our triumph in the high growth category meant we were put through to the SME National Business Awards and were thrilled to be recognised with a Silver award towards the end of 2022. We've also recently been named Best Drug Development, Discovery and Contract Research Organisation, 2022 - United Kingdom, at the Global Health & Pharma Global Excellence Awards.
Domainex expands Executive and Management Teams to support ongoing growth
We’ve made a number of strategic internal promotions to strengthen our Executive and Management teams. This expansion marks a period of ongoing growth for Domainex, and the newly bolstered teams will be pivotal in driving further development of the company. Read more.
Strengthening partnerships to drive ongoing research
Some of our alliance partners visited our research campuses recently including Cresset, Enamine and Pharmidex to discuss our ongoing collaborations and how we can continue to work together to drive progress in drug discovery. We also visited our neighbours Metrion, an ion channel drug discovery focused CRO, at their facility at Granta Park.
Hit identification – selecting the best path to success
How can you select the best hit identification approach for your drug discovery project? Our new brochure compares High Throughput Screening, Virtual Screening and Fragment Screening. Download the brochure.
A multiplex functional in vitro high throughput assay to measure compound effects on the inflammasome
We have established a robust activity assay for screening compounds for inhibition of NLRP3 inflammasome with a range of readouts measured in a multiplexed manner. Download the white paper.
New recruits
We’re pleased to welcome Aidan Johnson, Andrea Bombana, Barbara Vaccari Cardoso, Brandmam Medapi, Charlotte Hampton, Gary Pitt, Govesh Ramsorrun, Hattie Barnes, Ibrahim Celiker, Jason Pembroke, Krishna Samaddar, Marieke Lamers, Michaela Buerdsell, Nicholas Rose, Peter Griffin, Philip Rawlins, Robyn Presland, Sarah Mills-Pryke and Sophie Bell. Visit our website to view the current available opportunities and find out more about working at Domainex.
Upcoming events
Research & Innovation 2023
29th-30th March | Cambridgeshire, UK
BioTrinity
25th-26th April | London, UK
34th Medicinal Chemistry in Eastern England
27th April | Hatfield, UK
